ReviewEULAR rheumatology open2026
Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review.
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease with a complex a multifactorial pathophysiology. Due to difficulty recognising patients with SLE in an early stage, diagnostic delay is very common, which can result in the accumulation of organ damage. Some immunological signs, such as the presence of autoantibodies, have previously been shown to be present in patients with SLE, even before the onset of the first symptoms. This makes these immunological signs a prime target to improve the diagnostic process. In this article, we review recent studies investigating the use of biomarkers for diagnostics, including autoantibodies, other serum biomarkers, biomarkers in other bodily materials, circulating RNAs, and gene expression profiles. We discuss their place in the pathophysiology of SLE and their potential to improve and expedite the diagnostic process for patients with SLE.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.